Related Experiment Video
Updated: Feb 5, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
Immunoengineering through cancer vaccines - A personalized and multi-step vaccine approach towards precise cancer
Lien Lybaert1, Karim Vermaelen2, Bruno G De Geest1
1Department of Pharmaceutics, Ghent University, Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium.
Abstract:
During the last decade anti-tumor immune-therapy has opened novel opportunities to efficiently combat cancer progression. The introduction of DC- and CAR T-cell based therapies as well as the successful application of antibody-based inhibitor of immune checkpoints (CTLA-4, PD1 and PDL1) have boosted the field and led to an overall benefit for many patients. In situ cancer vaccination is an attractive strategy to further improve the therapeutic outcome, especially towards a more personalized and individually tailored immune response against the patient's mutanome. Nanoparticle-based delivery platforms can assist in combination treatments e.g. with multiple immune stimulatory signales (PAMPs and DAMPs) to increase the probability of evoking broader and all-embracing cytotoxic and memory T-cell responses. In this review, various approaches and hurdles of cancer vaccination are discussed including the beneficial contributions of the thriving field of nanoparticle design and functionalization, which may further boost the development of cancer immunotherapeutics.
Insights
Cancer immunotherapies like checkpoint inhibitors and cell therapies show promise. In situ cancer vaccination, enhanced by nanoparticles, offers a personalized approach to improve anti-tumor immune responses and patient outcomes.
Area of Science:
- Oncology
- Immunology
- Nanotechnology
Background:
- Anti-tumor immunotherapy has advanced significantly with DC- and CAR T-cell therapies.
- Immune checkpoint inhibitors (CTLA-4, PD1, PDL1) have improved patient benefits.
- In situ cancer vaccination presents a strategy for personalized anti-tumor immunity.
Purpose of the Study:
- To review current approaches and challenges in in situ cancer vaccination.
- To highlight the role of nanoparticle-based delivery in enhancing cancer immunotherapeutics.
- To explore how nanoparticle design can improve T-cell responses against cancer.
Main Methods:
- Review of existing literature on cancer immunotherapy and vaccination strategies.
- Analysis of nanoparticle applications in delivering immune-stimulating signals (PAMPs and DAMPs).
- Discussion of challenges and opportunities in nanoparticle-based cancer vaccine development.
Main Results:
- Nanoparticle platforms can facilitate combination treatments for cancer.
- Delivery of multiple immune signals via nanoparticles can broaden cytotoxic and memory T-cell responses.
- Advancements in nanoparticle design are crucial for developing effective cancer immunotherapeutics.
Conclusions:
- In situ cancer vaccination holds potential for personalized cancer treatment.
- Nanoparticle-based delivery systems are key to optimizing cancer vaccine efficacy.
- Further development in nanoparticle functionalization can significantly boost cancer immunotherapeutics.
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Vaccinations
Multi-Step Reactions
Maslow's Humanistic Approach on Personality
Cancer
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...

